Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Drug Discovery📍 New York, NYFounded 2015
Current Valuation
$1.1B
as of 2022-Q1
UNICORN
QL Price
$1.1B
0% vs last round
QuantLogix's current estimate for Kallyope, published 2026-09-27 — in line with the last disclosed round of $1.1B (2022-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.1B
2022-Q1
weight 0.04
How this price has held up
No round has priced for Kallyope since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Kallyope, 2026-09-27 (7b58f74caa77a621).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Kallyope going public?
No. Kallyope is private and has not filed to go public. There is no S-1 on file.
What is Kallyope's valuation in 2026?
Kallyope is valued at $1.1B as of 2022-Q1, set by its Series D ($236M, Jan 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Kallyope filed an S-1?
No public S-1 is on file for Kallyope.
How much has Kallyope raised?
Kallyope has raised $479M in total, most recently a Series D of $236M in Jan 2022.
Is Kallyope publicly traded — can you buy Kallyope stock?
No. Kallyope is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Kallyope on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2015
HQ
New York, NY
Employees
64
Total Raised
$479M
Last Round
Series D — $236M (Jan 2022)
IPO Status
private
Fundraising Status
Series D · $236M · 4y 8mo ago
privateTotal raised $479M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$236M
Jan 2022
—
$1.1B
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
9
3 active · 2 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Obesity
Migraine · Acute Migraine
Latest trial start
2026-09
Name-verified against lead sponsor "Kallyope Inc." on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Kallyope as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechnologyHealth CareMedicalPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.